During 2024 and early this year, the biotech sector began to show signs of a structural recovery, supported by positive clinical data, regulatory approvals, lower interest rates, commercial execution and Johnson & Johnson’s acquisition of Intra-Cellular Therapies, one of BION’s core holdings. H
